Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCH351125 in moderate to severe chronic plaque psoriasis
NL-OMON21684Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Apr 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of ancriviroc besylate in psoriasis and plaque psoriasis, sponsored by Merck & Co. Primary endpoints: Effect on psoriatic plaque cellularity and Safety and tolerability. Started Apr 2004; status: active, not recruiting.
02
Drugs
ancriviroc besylate
03
Conditions
psoriasisplaque psoriasis
Beyond the preview
Go deeper on NL-OMON21684.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON21684.